Evidence map›Paper›PMID 35935194›Full record

ArticleFrontiers in microbiology2022

Study of CD27, CD38, HLA-DR and Ki-67 immune profiles for the characterization of active tuberculosis, latent infection and end of treatment.

Sergio Díaz-Fernández, Raquel Villar-Hernández, Zoran Stojanovic, Marco Fernández, Maria Luiza De Souza Galvão, Guillermo Tolosa, Adrián Sánchez-Montalva, Jorge Abad, María Ángeles Jiménez-Fuentes, Guillem Safont and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 3 countries.

Sergio Díaz-FernándezInstitut d'Investigació Germans Trias i Pujol, Barcelona, Spain.
Raquel Villar-HernándezInstitut d'Investigació Germans Trias i Pujol, Barcelona, Spain.
Zoran StojanovicCIBER Enfermedades Respiratorias, CIBERES, Instituto de Salud Carlos III, Madrid, Spain.
Marco FernándezPlataforma de Citometría, Institut d'Investigació Germans Trias i Pujol, Barcelona, Spain.
Maria Luiza De Souza GalvãoUnitat de Tuberculosi de Drassanes, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Guillermo TolosaUniversidad de la Frontera (UFRO), Temuco, Chile.
Adrián Sánchez-MontalvaInfectious Diseases Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain.
Jorge AbadCIBER Enfermedades Respiratorias, CIBERES, Instituto de Salud Carlos III, Madrid, Spain.
María Ángeles Jiménez-FuentesUnitat de Tuberculosi de Drassanes, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Guillem SafontInstitut d'Investigació Germans Trias i Pujol, Barcelona, Spain.
Iris RomeroDepartament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Barcelona, Spain.
Josefina SabriàHospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain.
Cristina PratInstitut d'Investigació Germans Trias i Pujol, Barcelona, Spain.
Jose DomínguezInstitut d'Investigació Germans Trias i Pujol, Barcelona, Spain.
Irene LatorreInstitut d'Investigació Germans Trias i Pujol, Barcelona, Spain.
Universitat Autònoma de Barcelona · ESInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESVall d'Hebron Hospital Universitari · ESCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESHospital de Sant Joan Despí Moisès Broggi · ESHospital Universitari Germans Trias i Pujol · ESInstituto de Salud Carlos III · ESUniversidad de La Frontera · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Current blood-based diagnostic tools for TB are insufficient to properly characterize the distinct stages of TB, from the latent infection (LTBI) to its active form (aTB); nor can they assess treatment efficacy. Several immune cell biomarkers have been proposed as potential candidates for the development of improved diagnostic tools. Objective: To compare the capacity of CD27, HLA-DR, CD38 and Ki-67 markers to characterize LTBI, active TB and patients who ended treatment and resolved TB. Methods: Blood was collected from 45 patients defined according to clinical and microbiological criteria as: LTBI, aTB with less than 1 month of treatment and aTB after completing treatment. Peripheral blood mononuclear cells were stimulated with ESAT-6/CFP-10 or PPD antigens and acquired for flow cytometry after labelling with conjugated antibodies against CD3, CD4, CD8, CD27, IFN-γ, TNF-α, CD38, HLA-DR, and Ki-67. Conventional and multiparametric analyses were done with FlowJo and OMIQ, respectively. Results: The expression of CD27, CD38, HLA-DR and Ki-67 markers was analyzed in CD4 Conclusion: Our study independently confirms that CD27

Indexed as

activation markersclusterflow cytometryimmune responsemultiparametric analysisMycobacterium tuberculosisT-cellstreatment

Identifiers

PMID35935194
PMCPMC9354672
OpenAlexW4286488537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.